• FDA Approves Degevma, Biosimilar to Xgeva

    FDA Approves Degevma, Biosimilar to Xgeva
    Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved the biosimilar Degevma (denosumab-adet, Teva) for all indications of its reference product, Xgeva (denosumab, Amgen). These include:• preventing bone complications in adults with advanced cancer that has spread to the bone;• treating adults and skeletally mature adolescents with giant cell tumor of bone; and• treating hypercalcemia of malignancy.Degevma is Teva’s second bi
  • Financial Success Hinges on Proactive Enterprise Planning

    Financial Success Hinges on Proactive Enterprise Planning
    figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }McMahon Group.By Gina ShawHealth systems are looking to pharmacy to strengthen their finances, but many lack tools to track 340B performance or dedic

Follow @newsl_pharmacy on Twitter!